Calyx and Invicro Merge to Lead Medical Imaging Solutions for Clinical Research
Calyx and Invicro have reached an agreement to merge, forming a global leader in medical imaging and software solutions for the clinical research community. The combined entity will offer comprehensive services spanning the R&D lifecycle, from discovery to post-marketing.
The merger will see Calyx acquiring 100% of Invicro from its current owner, REALM IDx, Inc., subject to regulatory approvals and customary closing conditions, expected to be completed in Q2 2024. With approximately 2,000 employees across ten sites in the US, Europe, and Asia, the Group will provide a full suite of solutions to clients worldwide.
Both Calyx and Invicro bring complementary expertise and extensive experience in supporting clinical and research trials, including oncology and the central nervous system. The merged entity will enhance research and development capabilities, offering scientific and service support in preclinical and exploratory work.
David Herron, CEO of Calyx, expressed excitement about the merger, emphasizing the combined scientific talent, service offerings, and international presence that will establish the Group as an industry leader. Edward Hogan, COO of Invicro, highlighted the opportunity to unite skilled teams to accelerate the development of life-saving therapies across various therapeutic areas.
Following the transaction, efforts will focus on integrating the two companies while ensuring continued high-quality service and support for customers.
Related posts:
SHL Medical Partners with Lifecore Biomedical to Advance Drug Delivery Solutions
Clinical Trials 101: What You Need to Know About Medical Research
Amplifying the Patient Voice in Clinical Research Technology Development – Mike Cioffi
Global CD3 Antibodies Market Research Report 2023-2028 Highlights Steady Growth and Clinical Development Focus on Cancer Indications
